COVID-19 Interim Exclusion Guidance for Schools

Decision Tree for Excluding Symptomatic Individuals from Pre-K, K-12 Schools and Day Care Programs

Exclude if ANY of the following symptoms are present: Fever (100.4°F or higher), new onset of moderate to severe headache, shortness of breath, new cough, sore throat, vomiting, diarrhea, new loss of sense of taste or smell, fatigue from unknown cause, muscle or body aches from unknown cause.

School health officials should exclude when suspicion of COVID is high due to other symptoms.

Testing is Strongly Recommended for ALL Persons with COVID-19-Like Symptoms, Regardless of Vaccination Status.

Mask and Vaccine Requirements FAQ's

On September 3, 2021, the Governor signed Executive Order 21-22 which requires all individuals over the age of 2 and who can medically tolerate a face covering to wear a face covering when in indoor public places. The Executive Order also requires health care workers, school personnel, higher education personnel and students, and employees and contractors of state-owned or operated congregate facilities to be fully vaccinated, as described in the Order.

Face Covering Guidance

Who is required to wear a face covering indoors?

All individuals the age of 2 or over who can medically tolerate a face covering are required to wear a face covering over their nose and mouth when in an indoor public place.

All employees must wear face coverings in indoor workplaces.

Vaccine Provider Instructions

Guiding Principles for Providers

In order to promote a fair process for vaccine administration while vaccine supply is limited, the Illinois Department of Public Health (IDPH) is requiring all providers to help ensure that vaccine recipients self-verify their eligibility for the applicable prioritization group. Self-verification ensures the recipient truthfully indicates (verbally or otherwise) their specific category of eligibility to receive the vaccine.

Providers, as a best practice, will also request documentation or proof, such as personal identification, employee verification, or documentation of a qualifying health condition or disability to confirm the individual is in the priority population being served.

Guidance Affirming Non-Discrimination in Medical Treatment

This guidance is to affirm and supplement the State of Illinois’ April 10, 2020 Guidance Relating to Non-Discrimination in Medical Treatment for Novel Coronavirus 2019 (COVID-19). Federal and State civil rights laws, including the Illinois Human Rights Act, prohibit discrimination in the delivery of healthcare and support the rendering of ethical, non-discriminatory decisions. These principles have equal and ever-important application in the context of administering the COVID-19 vaccine.

Monoclonal Antibodies

If your COVID-19 test result is positive, you may be able to receive a medication called a monoclonal antibody. The names of these medicines are bamlanivimab and casirivimab/imdevimab. They have been made available for emergency use during COVID-19.

These medications are used ONLY in mild or moderate cases of COVID-19, in high-risk adults and children. You cannot take these medicines if you are already in the hospital or using oxygen.

High risk means you have at least one of the following conditions:

  • Obesity
  • Chronic kidney disease
  • Diabetes
  • Immunosuppressive disease
  • You take medicine that suppresses your immune system
  • 65 years of age or older
  • Less than 65 years with certain diseases of the heart, blood, or lung.

If you have a positive COVID-19 test and you are high risk; contact your healthcare professional as soon as possible. You must begin this therapy right away for it to be helpful.

COVID-19 Vaccine

Quarantine Guidance

On December 2, 2020, the Centers for Disease Control and Prevention (CDC) released new options for public health authorities to consider for establishing quarantine time frames for contacts of persons with SARS-CoV-2. Click here to review the full details on these new options.

The CDC currently recommends a quarantine period of 14 days. Further, local public health authorities determine and establish quarantine options for their jurisdictions and may decide to continue using a 14-day period and/or shortened options for certain lower risk close contacts. However, the following options to shorten quarantine are acceptable alternatives:

Local Health Department BinaxNOW Allocation Guidance

Background

The Federal Government has begun a distribution program of a new antigen test: the Abbott BinaxNOW. The Abbott BinaxNOW test is a fast-acting antigen test granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to detect the presence of SARS-CoV-2 viral protein. The BinaxNOW test is administered through an anterior nares swab that is then inserted into a credit-card sized test, where a reagent is added. These tests are inexpensive, point-of-care (POC) tests, with results available within 15 minutes. This distribution program has two separate channels:

Pages

Subscribe to RSS - Local Health Departments